Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lithium Americas Corp (LAC) vs Pfizer Inc (PFE) Price & Performance

Lithium Americas CorpTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Lithium Americas Corp vs Pfizer Inc — how do they compare? Lithium Americas Corp trades at $3.29 (market cap $1.18B), while Pfizer Inc trades at $26.34 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 128.6× Lithium Americas Corp's market cap, and Pfizer Inc pays a 6.46% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.

LACPFE
Market Cap
$1.18B$151.73B
Sector
Basic MaterialsHealth
52-Week High
$10.05$28.56
52-Week Low
$2.71$23.60
Enterprise Value
$1.29B$203.22B
Volume
29,869,932
Dividend Yield
6.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lithium Americas Corp

Lithium Americas Corp. (LAC) trades at $3.30, up 1.54% today, with a bullish technical signal from moving averages but negative profitability metrics including an ROE of -11.35% and net loss of $122.09 million in 2025. Recent news highlights a $175 million financing to strengthen the balance sheet as Thacker Pass approaches peak construction, though earnings have been volatile with mixed quarterly beats and misses.

The outlook is balanced: analyst consensus shows 47% buy ratings with no sells, reflecting optimism on lithium demand, but high execution risk remains given negative cash flow from operations and substantial capital needs. Upside depends on successful project development, while downside risks include funding pressures and commodity price volatility.

Pfizer Inc

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lithium Americas Corp

Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.

Read more on LAC

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE